NHS in-patient addiction unit set to close
The only NHS-run inpatient drug and alcohol unit in the west is to close despite a campaign to save it.
The Acer Unit, based in the grounds of Southmead Hospital in Bristol, will close its doors at the end of June this year.
Avon and Wiltshire NHS Mental Health Partnership (AWMHP), which runs the unit, said a fall in patient numbers due to a shift to community-based treatment meant it was no longer financially viable.
The AWMHP board made the decision to close the unit on Wednesday, noting only 45% of its beds are in regular use.
More news stories for Bristol
Watch the latest Points West
Listen to the latest news for Bristol
The meeting heard the trust has so far financed a £1.3m budget shortfall, but that this sum is due to reach £1.7m in the next financial year.
The unit was initially due to close at the end of March, but this was delayed following a campaign by a the Save the Acer group.
In an online petition, it described the Acer as "a vital cog in the wheel of recovery from addiction".
The group raised concerns that there are currently no plans to open an equivalent in-patient unit in the region.
In 2024, Bristol City Council had re-tendered its community drug and alcohol service and national provider Turning Point was awarded the contract.
Turning Point has now launched its "Horizons" programme in partnership with several local organisations to offer services including assessment, interventions, drug prescription and recovery support.
It will also offer alternative routes to accessing inpatient detox services when necessary.
In a statement, AWMHP said: "There will be no impact on current patients who are all scheduled to complete their treatment prior to the unit closing.
"We are also working closely with Turning Point as part of Horizons, the new community drug and alcohol services provider in Bristol from April 1, to continue supporting a safe transfer of those services."
Steve Rice, founder of the Save the Acer campaign, struggled with heroine addiction for 20 years, and has now been in recovery for 34 years.
He was sceptical about the efficacy of community-based treatments, adding that in his experience they were rarely successful for long-term addicts.
He told the BBC he feared for people aged in their 50s and 60s, often facing multiple health conditions, who will not be able to pay for private treatment.
"If you've got money you can get a detox but the people who go to the Acer, they are the little coins at the funfair machine that pushes coins backwards and forwards," he said.
"They are the people right at the edge. Their next stop is to fall off. These are the people that get treated in NHS detoxes."
A spokesperson for Bristol City Council said: "We are grateful to AWP for the provision of this service to date and thank staff at the Acer Unit for their passion and commitment.
"Bristol's new Horizons Drug and Alcohol service are working closely with the Acer Unit to ensure safe closure of the service.
"Bristol clients will have treatment options, including inpatient detox, put in place according to assessed clinical and other needs."
Follow BBC Bristol on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Closure of NHS detox unit delayed after campaign
Petition launched to keep city's detox unit open
Music offers healing at addicts' support group
AWMHP
Bristol City Council
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Time to face the harsh realities of spending orthodoxy
Labour came to power fatuously parroting the word 'change' and yet has shown itself to be the same old tax and spending party it has always been. What it meant was a change of party in office not a change of direction. Not only have taxes gone up but so-called protected spending is set to rise despite record debt levels. Yet if ever a public policy has been tested to destruction surely it is the notion that the NHS will improve if only more money is thrown at it. Even Sir Keir Starmer and Wes Streeting, the Health Secretary, are on record as saying that higher health spending is not the answer to the endemic flaws in the health service and yet another £30 billion is to be announced for the next three years on top of the £22 billion handed over after last year's general election, much of which went on pay and showed nothing in the way of productivity improvement. No mainstream politician is prepared to acknowledge that the problem with the NHS is the fact it is a nationalised industry with all the inherent inefficiencies associated with such. Most other advanced economies in Europe and elsewhere have social insurance systems which work better. But the insistence in Britain of cleaving to the 1948 'founding principle' that treatment should be free at the point of delivery has become a quasi-religious doctrine that few dare challenge. Only Nigel Farage has questioned the wisdom of continuing with a system that patently fails to achieve what others manage to do but has been noticeably quiet on the subject recently because Labour will exploit it mercilessly to see off the Reform people that they will have to pay for something they have always had for free is even more difficult when political parties are prepared to see the health system get worse rather than reform it. The same is true of welfare. Taking benefits from people, even when they are payments introduced just a few years ago like the winter fuel allowance, is hard if the reasons are not explained and the issue is 'weaponised' by opponents. Yet unless the welfare budget is brought under control it will bankrupt the country. If change is to mean anything then we need politicians finally to understand the extent of the country's difficulties and make decisions accordingly. Will we see that from the Chancellor on Wednesday? Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
5 hours ago
- Yahoo
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical care for the neurodevelopmental condition. A study published this week in the Journal of Affective Disorders has found that greater awareness and acceptance around the disorder has led to more people seeking help. The research, led by a team at King's College, London, debunks claims that the disorder is 'naturally' on the rise. The data comes as a national taskforce in England investigates what this rising demand for support means for the NHS. Figures published in May 2025 by NHS England estimated there were nearly 2.5 million people in England with ADHD. This includes more than 550,000 currently waiting for an assessment. Every month 20,000 more people are referred for support, a rise of 13% compared to last year. Pharmaceutical Technology looks at some of the current options in the UK and casts an eye ahead to what the future drug landscape might contain. The first choice for patients with ADHD is methylphenidate, which belongs to a class of drugs called central nervous system (CNS) stimulants. The drug, which works by blocking the reuptake of norepinephrine and dopamine, increases activity in the brain, including regions associated with attention and behaviour. It is known under the brand names Ritalin, manufactured by Novartis, and Johnson and Johnson's Concerta. There is also Equasym and Xenidate, among others. Lisdexamfetamine dimesylate is also used to treat patients with ADHD. Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and Vyvanse, both manufactured by Takeda. While stimulants are fast acting, with side effects felt soon after administration, non-stimulant drugs take longer, yet can offer an alternative if drugs like methylphenidate and lisdexamfetamine dimesylate do not work. While improving, access to pharmacological-based treatments is still impaired amid an ongoing global shortage that began in September 2023. Methylphenidate and lisdexamfetamine were primarily affected – the shortage arising due to a combination of manufacturing issues and increased global demand. A separate study published in The American Journal of Managed Care in March suggested that overdiagnosis of ADHD is fuelling the shortage of stimulation medications. One of the most advanced candidate drugs, and one with notable buzz surrounding it, is Axsome's Sunosi (solriamfetol). Sunosi, which is also an NDRI but not a conventional stimulant, met its primary endpoint in a Phase III trial (NCT05972044) earlier this year. The medication led to a 45% drop in ADHD symptoms. As measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), 150mg Sunosi dosed achieved average reductions from baseline of 17.7 points, compared to 14.3 points for placebo. Sunosi is already approved in the UK to treat excessive daytime sleepiness (EDS) in adults with narcolepsy, with or without cataplexy. Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication. In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals' Qelbree (viloxazine extended-release capsules). The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Originally approved for children in 2021, the FDA updated the drug's label in January this year to include adults. ADHD treatments were in the political crosshairs in the US recently. The disorder, along with autism, was singled out by the Trump administration for an 'over-utilisation of medication'. Pharmaceutical intervention remains a helpful part of managing the disorder, though it is part of a combination of treatments that also include coaching and lifestyle changes. "ADHD drugs back in the spotlight after study debunks rising prevalence" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
AIDS 5K Walk/Run cancelled due to wildfire smoke
LIVERPOOL, N.Y. (WSYR-TV) — The Canadian wildfire smoke in Central New York has caused the AIDS 5K Walk/Run to be cancelled. The run was originally scheduled for Sunday, June 8, 2025 at Onondaga Lake Park in Liverpool at the Saw Mill Creek Shelter. The decision to cancel the event was made because the air quality at this level can affect sensitive groups and others, especially during physical activity. The Air Quality Alert for Central New York will last until Sunday, 11:59 June 8. Organizers will share more information in the coming days. If anyone who has already registered for the event wishes to request a refund, they can contact klowe@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
